ARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on Thursday

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $15.46 million for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.

ARS Pharmaceuticals Price Performance

SPRY stock opened at $12.31 on Thursday. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -24.14 and a beta of 1.04. The business's fifty day moving average price is $11.93 and its two-hundred day moving average price is $13.09. ARS Pharmaceuticals has a fifty-two week low of $7.55 and a fifty-two week high of $18.51.

Wall Street Analyst Weigh In

SPRY has been the topic of several analyst reports. Oppenheimer initiated coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They set an "outperform" rating and a $40.00 target price on the stock. Leerink Partners increased their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. William Blair reissued an "outperform" rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Raymond James increased their target price on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a report on Tuesday, January 14th. Finally, Scotiabank initiated coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $31.00.

Remove Ads

Insider Buying and Selling at ARS Pharmaceuticals

In other news, insider Sarina Tanimoto sold 100,000 shares of the firm's stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $11.67, for a total transaction of $1,167,000.00. Following the completion of the transaction, the insider now directly owns 1,098,499 shares in the company, valued at $12,819,483.33. This trade represents a 8.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Laura Shawver sold 50,000 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $12.31, for a total value of $615,500.00. Following the transaction, the director now owns 210,346 shares of the company's stock, valued at $2,589,359.26. This trade represents a 19.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 276,872 shares of company stock worth $3,222,416. 40.10% of the stock is currently owned by insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.